Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 237-748-4 | CAS number: 13967-50-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Acute oral toxicity study in rats by the procedure according to OECD401 guideline.
Acute dermal toxicity study in rats, limit dose procedure according to OECD402 guideline.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- November 5th - Novermber 21st 1991
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP compliant, follows standard guidelines. Available as an unpublished report, acceptable without restrictions.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 (Acute Toxicity (Oral))
- Deviations:
- no
- GLP compliance:
- yes
- Test type:
- standard acute method
- Limit test:
- no
- Species:
- rat
- Strain:
- other: Bor: WISW (SPFCpb)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Winkelmann Versuchtierzucht GmbH & Co. KG., D-4799 Borchen
- Age at study initiation: Males: 8 weeks; Females: 9 weeks
- Weight at study initiation: Males: 138 - 168 g; Females: 137 - 148 g
- Fasting period before study: Approx. 16 hours
- Housing: 1 animal per cage. Macrolon cages (type II).
- Diet (e.g. ad libitum): ssniff R, Special diet for rats. ad libitum.
- Water (e.g. ad libitum): ad libitum
- Acclimation period: ≥5 days under test conditions.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20.5 - 23°C
- Humidity (%): 40 - 60%
- Photoperiod (hrs dark / hrs light): 6 a.m.- 6 p.m. CET artififical lighting, 6 p.m. - 6 a.m. CET natural light-dark-rhythm. - Route of administration:
- oral: gavage
- Vehicle:
- water
- Remarks:
- desalted water
- Details on oral exposure:
- VEHICLE
Test item in aqueous solution.
MAXIMUM DOSE VOLUME APPLIED: 2.5 ml/kg b.w. - Doses:
- 10.0, 21.5, 46.4 mg/kg
- No. of animals per sex per dose:
- 5
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: observation for mortalities: 0.5, 1, 2, 4, 6, 24 hours, daily thereafter; Weighing: days 0, 7 and 14
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs - Statistics:
- LD50 values calculated by Probit analysis
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- 36.1 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- 14.6 - 66.9
- Remarks on result:
- other: Slope of dose response curve: 7.76
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- 24.4 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- 12.6 - 50.8
- Remarks on result:
- other: Slope of dose response curve: 4.56
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 29.2 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- 21.7 - 39.8
- Remarks on result:
- other: Slope of dose response curve: 6.45
- Mortality:
- At the 21.5 mg/kg treatment level 2 females were found dead at 24 hours.
At the 46.4 mg/kg treatment level 1 male was found dead at 4 hours. 3 further males and 5 females were found dead at 24 hours. - Clinical signs:
- other: No clinical signs were observed in the 10.0 mg/kg b.w. treatment group. At higher doses rats of both sexes showed slight to moderate hypokinesia, restrained gait, piloerection, clonic convulsions and sunken sides. One male in the 46.4 mg/kg group addition
- Gross pathology:
- No macroscopic changes were observed in animals surviving at 14 days.
Of those that had died earlier male animals showed reddened small intestine and glandular stomach whilst females showed severely bloated stomach and hemorrages were found in the glandular stomach. Male and females exhibited stomachs that were tightly filled with liquid. - Interpretation of results:
- Category 2 based on GHS criteria
- Conclusions:
- In a 14 day acute toxicity test on male and female rats the LD50 of potassium dicyanoaurate was found to be 29.2 mg/kg.
- Executive summary:
In a 14 day acute toxicity test on male and female rats the LD50 of potassium dicyanoaurate was found to be 29.2 mg/kg. The female rats in the study were found to be more sensitive than the males.
The study was conducted to GLP standards and in accordance with standard guidelines.
Reference
Table 1 - Body weights of the individual animals.
Dose (mg/kg) | Animal No. | Day 0 | Day 7 | Day 14 |
Males | ||||
10 | 1 | 153 | 197 | 222 |
2 | 156 | 201 | 239 | |
3 | 155 | 204 | 235 | |
4 | 160 | 204 | 233 | |
5 | 157 | 206 | 237 | |
21.5 | 11 | 167 | 200 | 246 |
12 | 156 | 192 | 233 | |
13 | 158 | 183 | 213 | |
14 | 159 | 195 | 234 | |
15 | 168 | 215 | 260 | |
46.4 | 21 | 160 | 189 | 221 |
22 | 164 | |||
23 | 164 | |||
24 | 158 | |||
25 | 138 | |||
Females | ||||
10 | 6 | 137 | 153 | 158 |
7 | 148 | 178 | 193 | |
8 | 145 | 155 | 158 | |
9 | 141 | 166 | 173 | |
10 | 142 | 165 | 170 | |
21.5 | 16 | 141 | 152 | 166 |
17 | 144 | 156 | 165 | |
18 | 145 | |||
19 | 140 | |||
20 | 143 | 159 | 167 | |
46.4 | 26 | 145 | ||
27 | 148 | |||
28 | 146 | |||
29 | 145 | |||
30 | 140 |
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 29.2 mg/kg bw
- Quality of whole database:
- One GLP-compliant study is available, performed according to OECD guideline and produced quality and reliable data.
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP compliant, follows standard guidelines. Available as an unpublished report, acceptable without restrictions.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.3 (Acute Toxicity (Dermal))
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- standard acute method
- Limit test:
- yes
- Species:
- rat
- Strain:
- other: CD / Crl: CD(SD)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, Research Models and Services, Sulzfeld, Germany
- Age at study initiation: approx. 8 weeks
- Weight at study initiation: 258 - 268 g (males), 222 - 252 g (females)
- Fasting period before study: Yes, feeding discontinued approx. 16 hours before administration of test item.
- Housing: During the 14-day observation period the animals were kept singly in MAKROLON cages (type III plus) with granulated textured wood (Granulat A2, J. Brandenburg, Germany) as bedding material.
- Diet (e.g. ad libitum): Commercial diet, ssniff® R/M-H V1534 (ssniff Spezialdiäten GmbH, 59494 Soest, Germany) ad libitum with exception of 16 h fasting period before administration of test item.
- Water (e.g. ad libitum): ad libitum
- Acclimation period: At least 5 days.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22°C ± 3°C
- Humidity (%): 55% ± 15%
- Photoperiod (hrs dark / hrs light): 12 h dark / 12 h light (about 150 lux at approx. 1.5 m room height)
IN-LIFE DATES: From: 17 July 2014 To: 24 July 2014 - Type of coverage:
- semiocclusive
- Vehicle:
- water
- Remarks:
- Aqua ad iniectabilia
- Details on dermal exposure:
- TEST SITE
- Area of exposure: 5 x 6 cm
- % coverage: 10 %
- Type of wrap if used: 8 layers gauze covered with a plastic sheet and secured with adhesive plaster.
REMOVAL OF TEST SUBSTANCE
- Washing (if done): No, residues of test item were not removed.
- Time after start of exposure: 24 hours
TEST MATERIAL
- Amount(s) applied (volume or weight with unit): 1.7255 mL/kg b.w. preparation based on volume. 10 g Potassium dicyanoaurate mixed with 5 g water resulting in suspension with the density of 1.7386 g/mL.
- Concentration (if solution): 2000 mg/kg b.w.
- Constant volume or concentration used: no
- For solids, paste formed: no, suspension with a density of 1.7386 g/mL was used. - Duration of exposure:
- Exposure time was 24 hours.
- Doses:
- One dose level of 2000 mg/kg b.w. was examined.
- No. of animals per sex per dose:
- 5 males and 5 females per dose
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: before and immediately, and 5, 15, 30, 60 min, as well as 3, 6, and 24 hours after application of test item.
- Necropsy of survivors performed: yes
- Other examinations performed: changes of skin and fur, eyes and mucous membranes, respiratory and circulatory function, autonomic and central nervous system and somatomotor activity as well as behaviour pattern, were observed at least once a day until all symptoms subsided, thereafter each working day. Attention was also paid to possible tremors, convulsions, salivation, diarrhoea, lethargy, sleep and coma. Observations on mortality were made at least once daily. Individual body weights were recorded before administration of the test item and thereafter in weekly intervals up to the end of the study. Changes in weight were calculated and recorded. The skin was observed for the development of erythema and oedema. At the end of the experiments, all animals were sacrificed, dissected and inspected macroscopically. All gross pathological changes were recorded. - Sex:
- male/female
- Dose descriptor:
- LD0
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- No mortalities observed during the test.
- Clinical signs:
- other: No clinical signs observed.
- Gross pathology:
- No macroscopic findings observed at necropsy.
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- According to the EC-Commission directive 67/548/EEC and its subsequent amendments Potassium dicyanoaurate requires no labelling.
The test material is not classified for acute dermal toxicity according to the EC Regulation 1272/2008 and subsequent regulations and according to the Globally Harmonized Classification System (GHS). - Executive summary:
Acute dermal toxicity study of Potassium dicyanoaurate was according to OECD guideline 402 and EC method B.3 in rats. The test was conducted according to GLP.
The test item Potassium dicyanoaurate was applied dermally, on the shaved intact dorsal skin to rats once for 24 hours. This treatment was followed by an observation period of 2 weeks.
Under the test conditions, a single dermal administration of 2000 mg Potassium dicyanoaurate/kg b.w. did not reveal any signs of toxicity. No animal died prematurely. All animals gained the expected weight throughout the whole experimental period. The LD50 was determined to be >2000 mg/kg b.w. According to the EC-Commission directive 67/548/EEC and its subsequent amendments Potassium dicyanoaurate requires no labelling. The test material is not classified for acute dermal toxicity according to the EC Regulation 1272/2008 and subsequent regulations and according to the Globally Harmonized Classification System (GHS).
Reference
Table 1. Summary of effects
Symptoms/Criteria |
Potassium dicyanoaurate 2000 mg/kg b.w. (n=5) |
|
|
males |
females |
Clinical signs |
None |
None |
Skin reactions |
None |
None |
Mortality 6 h |
0 |
0 |
24 h |
0 |
0 |
7 d |
0 |
0 |
14 d |
0 |
0 |
Mean body weight gain (g) Start |
264.6 |
237.2 |
After 7 d |
297.6 (+12.5) |
238.8 (+0.7) |
After 14 d |
351.6 (+32.9) |
256.8 (+8.3) |
Inhibition of bodyweight gain |
None |
None |
Necropsy findings |
None |
None |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Quality of whole database:
- One GLP-compliant study is available, performed according to OECD and EU guidelines and produced quality and reliable data.
Additional information
The acute oral toxicity of potassium dicyanoaurate was tested in rats following OECD guideline 401 and EU method B.1. Rats were orally gavaged with a single dose of potassium dicyanoaurate solution in desalted water at nominal concentrations of 10.0, 21.5 and 46.4 mg/kg, followed by a 14-day observation period. The LD50 was calculated to be 24.4 mg/kg bw for females and 36.1 mg/kg bw for males, giving an overall LD50 of 29.2 mg/kg bw. Signs of clinical toxicity were observed at 21.5 mg/kg bodyweight and higher (Berthold 1992).
In a limit test for acute dermal toxicity following OECD guideline 402 and EU method B.3, a single application of 2000 mg/kg bw potassium dicyanoaurate solution was applied occlusive on rats for 24 hours. No premature deaths or signs of toxicity were observed (Leuschner 2014). Potassium dicyanoaurate is not classified for acute dermal toxicity according to GHS and EC regulation 1272/2008.
Justification for selection of acute toxicity – oral endpoint
Only one study covering the endpoint but it is a Guideline study (OECD401) conducted to GLP standards.
Justification for selection of acute toxicity – dermal endpoint
Only one study covering the endpoint but it is a Guideline study (OECD402) conducted to GLP standards. No acute dermal toxicity or signs of clinical toxicity were observed at the limit dose of 2000 mg/kg bw silver cyanide.
Justification for classification or non-classification
According to GHS and EC regulation 1272/2008, potassium dicyanoaurate is classified as category 2 for acute oral toxicity based on a LD50 of 29.2 mg/kg bw. No classification for acute dermal toxicity is required as no toxicity effects were observed in a limit test at 2000 mg/kg bw.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.